Terran Biosciences
Transforming the lives of patients with neurological and psychiatric illnesses.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Series B | |
| Total Funding | 000k | ||
Related Content
A biotech platform company with a focus on developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.
Terran Biosciences is building a CNS-focused, tech-enabled drug development platform and is rapidly advancing a number of assets that include late-stage therapeutics for schizophrenia, Alzheimer's, and Parkinson's disease. The company's business model is centered on research and development of novel drugs and technologies, with the goal of commercializing them through licensing or direct sales after regulatory approval. Its target market is the global pharmaceutical and biotech industry for central nervous system disorders, and its clients are patients suffering from these conditions.
Keywords: drug development, neuropsychiatric disorders, CNS, therapeutics, biotech platform, schizophrenia, Alzheimer's, Parkinson's, clinical trials, pharmaceuticals